Robert J. Mayer
Impact in
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Hematology top 0.1%
- Acute Myeloid Leukemia Research
Papers in
- Oncology 163
- Colorectal Cancer Treatments and Studies 98
- Cancer Treatment and Pharmacology 36
- Colorectal Cancer Surgical Treatments 31
- Pancreatic and Hepatic Oncology Research 22
-
- Gastric Cancer Management and Outcomes 46
- Co-authors
- Peter C. Enzinger (8 shared papers)Jeffrey A. Meyerhardt (47 shared papers)Donna Niedzwiecki (95 shared papers)Charles S. Fuchs (55 shared papers)Daniel G. Haller (18 shared papers)Donna Hollis (40 shared papers)Leonard B. Saltz (38 shared papers)Richard M. Goldberg (59 shared papers)
- Journals
- Journal of Clinical Oncology (126 papers)Cancer (14 papers)Annals of Oncology (12 papers)Angewandte Chemie International Edition (11 papers)New England Journal of Medicine (10 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Robert J. Mayer
385 papers receiving 32.2k citations
Robert J. Mayer's Hit Papers
Peers
Comparison fields: 5 of 194
- Oncology 14.7k
- Hematology 3.4k
- Pathology and Forensic Medicine 3.5k
- Hepatology 1.5k
- Cancer Research 2.9k
Countries citing papers authored by Robert J. Mayer
This map shows the geographic impact of Robert J. Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Mayer more than expected).
Fields of papers citing papers by Robert J. Mayer
This network shows the impact of papers produced by Robert J. Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Mayer. The network helps show where Robert J. Mayer may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert J. Mayer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 393 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Esophageal Cancer Hit paper breakdown → | 2003 | 2124 |
| 2 | Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor Hit paper breakdown → | 2004 | 1383 |
| 3 | Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia Hit paper breakdown → | 1994 | 1033 |
| 4 | Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 Hit paper breakdown → | 2008 | 1006 |
| 5 | Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089 Hit paper breakdown → | 2003 | 886 |
| 6 | Systemic Therapy for Colorectal Cancer Hit paper breakdown → | 2005 | 848 |
| 7 | Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery Hit paper breakdown → | 1994 | 820 |
| 8 | National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 Hit paper breakdown → | 2001 | 714 |
| 9 | Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) Hit paper breakdown → | 2010 | 681 |
| 10 | Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 Hit paper breakdown → | 2006 | 538 |
| 11 | Carcinoid Tumors Hit paper breakdown → | 1999 | 519 |
| 12 | Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Hit paper breakdown → | 1998 | 509 |
| 13 | 2001 | 449 | |
| 14 | The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. Hit paper breakdown → | 1989 | 445 |
| 15 | 1997 | 445 | |
| 16 | 2005 | 429 | |
| 17 | 1995 | 421 | |
| 18 | 2006 | 419 | |
| 19 | 2008 | 398 | |
| 20 | 2000 | 379 |
About Robert J. Mayer
Robert J. Mayer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Pathology and Forensic Medicine, having authored 393 papers that have together received 33.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (98 papers), Gastric Cancer Management and Outcomes (46 papers), Cancer Treatment and Pharmacology (36 papers), Genetic factors in colorectal cancer (35 papers), Acute Myeloid Leukemia Research (32 papers), Colorectal and Anal Carcinomas (32 papers), Colorectal Cancer Surgical Treatments (31 papers) and Pancreatic and Hepatic Oncology Research (22 papers). The work is most often cited by research in Oncology (14.7k citations), Hematology (3.4k citations), Pathology and Forensic Medicine (3.5k citations), Hepatology (1.5k citations) and Cancer Research (2.9k citations). Robert J. Mayer has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Peter C. Enzinger, Jeffrey A. Meyerhardt, Donna Niedzwiecki, Charles S. Fuchs, Daniel G. Haller, Donna Hollis, Leonard B. Saltz, Richard M. Goldberg, John S. Macdonald and Paul J. Catalano. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Annals of Oncology, Angewandte Chemie International Edition and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.